Iressa Clinical Development Timeline
Chronicle of the development and review of AstraZeneca’s tyrosine kinase inhibitor gefitinib for EGFR mutation-positive non-small cell lung cancer.
Chronicle of the development and review of AstraZeneca’s tyrosine kinase inhibitor gefitinib for EGFR mutation-positive non-small cell lung cancer.